Examine how the BioE3 Policy 2024 can transform India into a global biomanufacturing hub. What challenges remain?

Q. Examine how the BioE3 Policy 2024 can transform India into a global biomanufacturing hub. What challenges remain? (15 marks, 250-350 words)

Approved by the Union Cabinet on 24 August 2024, the BioE3 Policy — Biotechnology for Economy, Environment and Employment — seeks to shift India from a services-led biotech economy to high-performance biomanufacturing. With the bioeconomy rising from ~$10 billion (2014) to ~$190 billion in 2026 [1], the policy is the institutional scaffolding for the $300 billion target by 2030 [4].

How BioE3 can build a global biomanufacturing hub - Infrastructure backbone: creation of Biofoundries, Biomanufacturing Hubs and Bio-AI Hubs under the Department of Biotechnology (DBT), with BIRAC as implementing arm, bridges the lab-to-market "valley of death" [2]. - Thematic focus: six priority sectors — bio-based chemicals and enzymes, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, marine and space biotech — target import substitution in high-value molecules [2]. - Green growth: a regenerative bioeconomy model links manufacturing to net-zero goals through biopolymers and carbon capture, aligning with SDG 9 and SDG 13 [2]. - Employment and startups: biotech startups grew from about 50 in 2014 to 8,531 by 2023, showing an absorptive innovation base for skilled job creation [4]. - Demonstrated capability: the indigenous COVID-19 vaccine ecosystem established credibility as a trusted global supplier [1].

Challenges that remain - Low R&D intensity: gross R&D spending remains well under 1% of GDP, with limited private participation, unlike leading biomanufacturing economies. - Regulatory complexity: multiple clearances (GEAC, CDSCO, biosafety) slow scale-up despite single-window intent. - Skill and infrastructure gaps: shortage of fermentation-scale bioprocess engineers; hubs remain concentrated in a few western and southern clusters. - Feedstock and IP dependence: reliance on imported enzymes, reagents and foreign patents raises costs.

BioE3 is therefore necessary but not sufficient — its promise rests on execution. Sustained R&D financing through the ANRF, faster risk-proportionate regulatory clearance, and federal roll-out via state MoUs can convert policy intent into industrial capacity. Realised well, biomanufacturing can make India's growth simultaneously self-reliant, employment-rich and ecologically sustainable.

(~330 words)

Sources: 1. $10 Billion to $190 Billion Bioeconomy: India's Science Story touches New Heights in 12 Years, PIB (15 June 2026) — bioeconomy $10 bn (2014) to $190 bn (2026); indigenous vaccine capability 2. Cabinet approves BioE3 Policy for Fostering High Performance Biomanufacturing, PIB (24 August 2024) — Cabinet approval date, Biofoundry/Bio-AI/Biomanufacturing hubs, thematic sectors, regenerative bioeconomy 3. India's space economy at $8.4 billion, nearly 400 start-ups active after sector opened to private players, PIB (January 2026) — comparative policy-reform-led sectoral scale-up model 4. India's Bioeconomy to Touch $300 Billion by 2030, PIB — $300 bn 2030 target; biotech startup growth to 8,531